Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
29.18
+0.16 (0.55%)
Jan 29, 2026, 11:47 AM EST - Market open
Beam Therapeutics Employees
Beam Therapeutics had 510 employees as of September 30, 2025. The number of employees increased by 38 or 8.05% compared to the same quarter last year.
Employees
510
Change
38
Growth
8.05%
Revenue / Employee
$109,218
Profits / Employee
-$813,025
Market Cap
2.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 510 | 38 | 8.05% |
| Jun 30, 2025 | 509 | 48 | 10.41% |
| Mar 31, 2025 | 393 | 47 | 13.58% |
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Sep 30, 2024 | 472 | 33 | 7.52% |
| Jun 30, 2024 | 461 | -71 | -13.35% |
| Mar 31, 2024 | 346 | -177 | -33.84% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Sep 30, 2023 | 439 | -68 | -13.41% |
| Jun 30, 2023 | 532 | 56 | 11.76% |
| Mar 31, 2023 | 523 | 129 | 32.74% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Sep 30, 2022 | 507 | 201 | 65.69% |
| Jun 30, 2022 | 476 | 210 | 78.95% |
| Mar 31, 2022 | 394 | 178 | 82.41% |
| Dec 31, 2021 | 341 | 160 | 88.40% |
| Sep 30, 2021 | 306 | 140 | 84.34% |
| Jun 30, 2021 | 266 | 115 | 76.16% |
| Mar 31, 2021 | 216 | 98 | 83.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptive Biotechnologies | 619 |
| Arcutis Biotherapeutics | 342 |
| Tarsus Pharmaceuticals | 323 |
| Dyne Therapeutics | 240 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 181 |
| Viridian Therapeutics | 143 |
| Disc Medicine | 142 |
BEAM News
- 15 days ago - Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 15 days ago - Beam Therapeutics: Pivoting From Platform To Execution Stage - Seeking Alpha
- 17 days ago - Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition - GlobeNewsWire
- 5 weeks ago - Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
- 2 months ago - Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - GlobeNewsWire
- 3 months ago - Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire